Vigil Neuroscience (NASDAQ:VIGL) announced Tuesday that the U.S. Food and Drug Administration (FDA) has removed the partial ...

Vigil Neuroscience said the Food and Drug Administration removed a partial clinical hold on its ongoing Phase 1 clinical trial of a treatment for Alzheimer's disease, VG-3927. The clinical-stage ...

The FDA has approved a groundbreaking new drug to slow the progression of Alzheimer's disease in its early stages, offering ...

For Lennart Mucke, MD, founding director of the Gladstone Institute of Neurological Disease, these new drugs mark an ...

A team of scientists, including researchers from Penn State, have found that a drug being developed for cancer treatment ...

The new Alzheimer’s drug Kinsula is offering hope for patients by slowing down the progression of the disease. Neurologist Dr. Mauricio Concha administered the drug ...

Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any ...

THURSDAY, Sept. 11, 2024 (HealthDay News) -- Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab ...

Kearney physician Dr. Bradley Rodgers will soon offer Kisunla, the first drug proven to slow the early onset of Alzheimer’s.

As Gladstone Institutes commemorates World Alzheimer’s Month, Lennart Mucke, MD, discusses what’s next for Alzheimer’s ...

Leqembi, an Alzheimer's drug from Biogen and Eisai, faces hurdles with respect to reimbursement and diagnostic uncertainties, diagnostic test requirements and the need for regular brain scans, CNBC ...

Registered dietitian nutritionist Carrie Dennett explains what nicotinamide adenine dinucleotide, or NAD, is and if it has ...